Relmada Therapeutics Files 8-K
Ticker: RLMD · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure
TL;DR
Relmada Therapeutics filed an 8-K on Aug 29, 2025. Details TBD.
AI Summary
Relmada Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting a Regulation FD Disclosure. The company, formerly known as Camp Nine, Inc., is incorporated in Nevada and headquartered in Coral Gables, Florida. This filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This 8-K filing indicates a significant event or disclosure by Relmada Therapeutics, Inc. that is being communicated to the public and the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a Regulation FD disclosure, which typically doesn't involve immediate financial risk but rather information dissemination.
Key Players & Entities
- RELMADA THERAPEUTICS, INC. (company) — Registrant
- Camp Nine, Inc. (company) — Former company name
- August 29, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Coral Gables, FL (location) — Principal executive offices location
FAQ
What is the exact nature of the Regulation FD Disclosure being made by Relmada Therapeutics?
The provided text of the 8-K filing does not specify the exact nature of the Regulation FD Disclosure.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 29, 2025.
What is Relmada Therapeutics, Inc.'s state of incorporation?
Relmada Therapeutics, Inc. is incorporated in Nevada.
What was Relmada Therapeutics, Inc.'s former company name?
Relmada Therapeutics, Inc.'s former company name was Camp Nine, Inc.
Where are Relmada Therapeutics, Inc.'s principal executive offices located?
Relmada Therapeutics, Inc.'s principal executive offices are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Filing Stats: 481 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-09-02 07:30:53
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The NASDAQ
Filing Documents
- ea0255475-8k_relmada.htm (8-K) — 25KB
- 0001213900-25-082910.txt ( ) — 186KB
- rlmd-20250829.xsd (EX-101.SCH) — 3KB
- rlmd-20250829_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250829_pre.xml (EX-101.PRE) — 22KB
- ea0255475-8k_relmada_htm.xml (XML) — 4KB
01 Regulation
Item 7.01 Regulation FD Disclosure. On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the "Company"), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 2, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 2